ACHN-975 is primarily investigated for its potential applications in the field of antimicrobial therapy. It is a novel antibiotic designed to target and inhibit bacterial infections, particularly those caused by Gram-negative pathogens. Its mechanism of action involves blocking the activity of a specific bacterial enzyme, which is crucial for bacterial survival, making it effective against drug-resistant strains. Research has shown promise in treating infections such as pneumonia, urinary tract infections, and bloodstream infections. Additionally, ACHN-975 is being studied for its potential use in combination therapies to enhance efficacy and reduce the risk of resistance development. Its development represents a significant step forward in addressing the growing challenge of antibiotic resistance in clinical settings.